Industries > Pharma > Global Graft versus Host Disease (GVHD) Market 2019-2029

Back to Pharma Reports

Global Graft versus Host Disease (GVHD) Market 2019-2029

Acute, Chronic and Prophylaxis GVHD

PAGES: 162

PRODUCT CODE: PHA0384

SUBMARKET: Therapeutic Drugs

SKU: PHA0384 Categories: Pharma, Therapeutic Drugs Tags: PHA0346, PHA0384, PHA0458, PHA0731

The global graft versus host disease market is expected to grow at a CAGR of 7% from 2016-2021 and CAGR of 3% from 2019-2029. The market is expected to grow at a CAGR of 6% from 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn in 2026.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 162-page report you will receive 62 tables and 76 figures – all unavailable elsewhere.

The 162-page report provides clear detailed insight into the Graft versus Host Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Revenue and growth forecasts to 2027 for the global GVHD market

• Revenue and growth forecasts to 2027 for the leading countries

• GVHD patient number forecast to 2027 per leading country, segmented into total allogenic cases, first allogenic cases, acute GVHD and chronic GVHD

• Revenue and growth forecasts to 2027 for the leading segments of the GVHD market by treatment type

• Revenue and growth forecasts to 2027 for the leading drugs in the GVHD market.

Individual revenue forecasts to 2027 by treatment type:
• Prophylaxis GVHD
• Chronic GVHD
• Acute GVHD

Individual revenue forecasts to 2027 by product:

• Corticosteroids
– Methylprednisolone
– Budenofalk (effeverscent)

• ATG therapies
– Available ATG therapy (Thymoglobulin)
– Atege-Fresenius

• IL2Rα (CD25) inhibitors
– Simulect (Basiliximab)
– Leukotac (inolimomab)

• TNFα inhibitors
– Remicade (Infliximab)
– Enbrel (Etanercept)
– Co-stimulatory blockers
– Orencia (abatacept)
– Nulojix (belatacept)

• Other biologics
– Lemtrada (Alemtuzumab)
– Rituxan/MabThera (rituximab)
– Begedina (bt/9 anti-CD26)

• Calcineurin inhibitors
– Cyclosporine

• mTOR inhibitors
– Rapamune (sirolimus)
– Certican (everolimus)

• SOT therapies
– CellCept/Myfortic (mycophenolate mofetil)
– Prograf (tacrolimus)

• Anti-neoplastic therapies
– Velcade (bortezomib)
– Gleevec (imatinib)
– Methrotrexate
– Nipent (pentostatin)
– Cyclophosphamide

• Stem Cell Treatments
– In situ preparations of mesenchymal cells
– Prochymal (remestemcel-L)

• Extracorporeal Photophoresis
– Uvadex (Therakos)

Individual revenue forecasts to 2027 by country, further segmented by treatment type and by product:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

GVHD patient number forecasts to 2027 per leading country, segmented into:
• total allogenic cases
• first allogenic cases
• acute GVHD
• chronic GVHD

Visiongain’s study is intended for anyone requiring commercial analyses for the GVHD market. You find data, trends and predictions.

Buy our report today Global Graft versus Host Disease (GVHD) Market 2019-2029: Acute, Chronic and Prophylaxis GVHD.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Report Overview

1.1 Global Graft versus Host Disease (GVHD) Market Overview

1.2 Why You Should Read This Report

1.3 How This Report Delivers

1.4 Key Questions Answered by This Analytical Report

1.5 Who is This Report For?

1.6 Methodology

1.6.1 Primary Research

1.6.2 Secondary Research

1.6.3 Market Evaluation & Forecasting Methodology

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2. Graft versus Host Disease Background

2.1 Graft versus Host Disease Definition

2.2 Graft versus Host Disease Classifications

2.2.1 Acute graft-versus-host disease (GVHD)

2.2.2 Chronic graft-versus-host disease (GVHD)

2.2.3 Symptoms of Graft versus Host Disease

2.3 Grades of GvHD

3 Global GVHD Market 2016

3.1 Global GVHD Market, 2016

4 Global GHVD Market Forecast, 2016-2027

4.1 Key Findings

4.2 Key Market Challenges and Opportunities

5 Global GVHD Market by Product 2019-2029

6 Regional GVHD Market 2016-2026

6.1 Regional Breakdown of the GVHD Market, 2016

6.2 United States GVHD Market Forecast 2019-2029

6.2.1 U.S. GVHD Market Forecast by Products 2019-2029

6.2.2 U.S. GVHD Patient Number Forecast 2016-2027

6.3 Japan GVHD Market Forecast 2019-2029

6.3.1 Japan GVHD Market Forecast by Products 2019-2029

6.3.2 Japan GVHD Patient Number Forecast 2016-2027

6.4 France GVHD Market Forecast 2019-2029

6.4.1 France GVHD Market Forecast by Products 2019-2029

6.4.2 France GVHD Patient Number Forecast 2016-2027

6.5 Germany GVHD Market Forecast 2019-2029

6.5.1 Germany GVHD Market Forecast by Products 2019-2029

6.5.2 Germany GVHD Patient Number Forecast 2016-2027

6.6 Italy GVHD Market Forecast 2019-2029

6.6.1 Italy GVHD Market Forecast by Products 2019-2029

6.6.2 Italy GVHD Patient Number Forecast 2016-2027

6.7 Spain GVHD Market Forecast 2019-2029

6.7.1 Spain GVHD Market Forecast by Products 2019-2029

6.7.2 Spain GVHD Patient Number Forecast 2016-2027

6.8 United Kingdom GVHD Market Forecast 2019-2029

6.8.1 United Kingdom GVHD Market Forecast by Products 2019-2029

6.8.2 United Kingdom GVHD Patient Number Forecast 2016-2027

6.9 Key Findings

6.10 Treatment Goals

7 Leading Drugs in the Graft versus Host Disease (GVHD) Market 2019-2029

7.1 Temcell HS

7.1.1 Introduction

7.1.2 Safety & Efficacy

7.1.3 Advantages & Disadvantages

7.1.4 Total Temcell Sales, 2016-2027

7.2 Remicade

7.2.1 Introduction

7.2.2 Safety & Efficacy

7.2.3 Advantages & Disadvantages

7.2.4 Total Remicade Sales, 2016-2027

7.3 Lemtrada

7.3.1 Introduction

7.3.2 Safety & Efficacy

7.3.3 Advantages & Disadvantages

7.3.4 Total Lemtrada Sales, 2016-2027

7.4 Velcade

7.4.1 Introduction

7.4.2 Safety & Efficacy

7.4.3 Advantages & Disadvantages

7.4.4 Total Velcade Sales, 2016-2027

7.5 Gleevac

7.5.1 Introduction

7.5.2 Safety & Efficacy

7.5.3 Advantages & Disadvantages

7.5.4 Total Gleevac Sales, 2016-2027

7.6 Rapamune

7.6.1 Introduction

7.6.2 Safety & Efficacy

7.6.3 Advantages & Disadvantages

7.6.4 Total Rapamune Sales, 2016-2027

7.7 Enbrel

7.7.1 Introduction

7.7.2 Safety & Efficacy

7.7.3 Advantages & Disadvantages

7.7.4 Total Enbrel Sales, 2016-2027

7.8 Orencia

7.8.1 Introduction

7.8.2 Safety & Efficacy

7.8.3 Advantages & Disadvantages

7.8.4 Total Orencia Sales, 2016-2027

7.9 Nulojix

7.9.1 Introduction

7.9.2 Safety & Efficacy

7.9.3 Advantages & Disadvantages

7.9.4 Total Nulojix Sales, 2016-2027

7.10 Grafalon (ATG-Fresenius S)

7.10.1 Introduction

7.10.2 Safety & Efficacy

7.10.3 Advantages & Disadvantages

7.10.4 Total ATG-Fresenius Sales, 2016-2027

8 Emerging Therapies in the Graft versus Host Disease (GVHD) Market 2019-2029

8.1 Leukotac (inolimomab)

8.1.1 Introduction

8.1.2 Clinical Development

8.1.3 Total Leukotac Sales, 2016-2027

8.2 Begedina (begelomab)

8.2.1 Introduction

8.2.2 Clinical Development

8.2.3 Total Begelomab Sales, 2016-2027

8.3 Budesonide/Budenofalk (effeverscent)

8.3.1 Introduction

8.3.2 Clinical Development

8.3.3 Total Budesonide/Budenofalk Sales, 2016-2027

9 Global Graft versus Host Disease (GVHD) Market Drivers & Barriers

9.1 Market Drivers

9.1.1 Orphan Designation

9.1.2 Increased clinical & Pre-clinical studies with positive results

9.1.3 Increased Collaborations & Acquisitions

9.1.4 Competition among biotech and pharmaceutical giants

9.1.5 Wide range of targets

9.2 Market Barriers

9.2.1 Side-effects of approved drugs

9.2.2 Economic Burden

9.2.3 Challenges in Drug Development

9.2.4 Social Burden

10 SWOT Analysis

11 Conclusion

11.1 GVHD Market Forecast

11.2 GVHD Regional Market Forecast

11.3 GVHD Market Segments

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 1.1 Global GVHD Market: Revenue ($m), AGR (%), CAGR (%) by Region, 2016-2020

Table 2.1 Definition of Acute and Chronic GvHD

Table 2.2 Glucksberg Clinical Stage of Acute GvHD

Table 2.3 Glucksberg Grade of Acute GvHD

Table 2.4 Global Scoring of cGvHD

Table 3.1 Global GVHD Market: Revenue ($m) and Market Share (%) by Segment, 2016

Table 4.1 Key Events and their Market Impact (2013-2027)

Table 4.2 Global GVHD Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027

Table 4.3 Global GVHD by Treatment Type Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 5.1 Global GVHD Market Forecast 2016-2027 ($m), AGR %, CAGR %)

Table 6.1 Global GVHD Market: Revenue ($m) and Market Share (%) by Region, 2016

Table 6.2 United States GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.3 United States GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.4 U.S. GVHD Market Forecast by Products: Revenue ($m), 2016-2027

Table 6.5 U.S. GVHD Patient Number Forecast, 2013-2026

Table 6.6 U.S. GVHD Patient Number Forecast, 2019-2029

Table 6.7 Japan GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.8 Japan GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.9 Japan GVHD Market Forecast by Products: Revenue ($m), 2016-2027

Table 6.10 Japan GVHD Patient Number Forecast, 2013-2026

Table 6.11 Japan GVHD Patient Number Forecast, 2019-2029

Table 6.12 France GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.13 France GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.14 France GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.15 France GVHD Patient Number Forecast, 2013-2026

Table 6.16 France GVHD Patient Number Forecast, 2019-2029

Table 6.17 Germany GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.18 Germany GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.19 Germany GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.20 Germany GVHD Patient Number Forecast, 2013-2026

Table 6.21 Germany GVHD Patient Number Forecast, 2019-2029

Table 6.22 Italy GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.23 Italy GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.24 Italy GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.25 Italy GVHD Patient Number Forecast, 2013-2026

Table 6.26 Italy GVHD Patient Number Forecast, 2019-2029

Table 6.27 Spain GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.28 Spain GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.29 Spain GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.30 Spain GVHD Patient Number Forecast, 2013-2026

Table 6.31 Spain GVHD Patient Number Forecast, 2019-2029

Table 6.32 United Kingdom GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.33 United Kingdom GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.34 United Kingdom GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 6.35 United Kingdom GVHD Patient Number Forecast, 2013-2026

Table 6.36 United Kingdom GVHD Patient Number Forecast, 2019-2029

Table 7.1 Temcell Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.2 Remicade Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.3 Lemtrada Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.4 Velcade Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.5 Gleevac Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.6 Rapamune Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.7 Enbrel Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.8 Orencia Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.9 Nulojix Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.10 ATG-Fresenius Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027Table 8.1 Leukotac Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 8.2 Begelomab Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027

Table 8.3 Budesonide/Budenofalk Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027Table 11.1 Global Graft versus Host Disease (GVHD) Market: Revenue ($m), AGR (%), CAGR (%), 2016, 2022, 2027

Table 11.2 Global GVHD Market: Revenue ($m), AGR (%), CAGR (%) by Region, 2016, 2022, 2027

Table 11.3 Global Graft versus Host Disease (GVHD) Market: Revenue ($m), AGR (%), CAGR (%) by Segment, 2016, 2022, 2027

List of Figures

Figure 2.1 Initiation and Evolution of GvHD

Figure 3.1 Global GVHD Market: Revenue ($m) by Segment, 2016

Figure 3.2 Global GVHD: Market Share (%) by Segment, 2016

Figure 4.1 Global GVHD Market: Revenue ($bn) 2016-2027

Figure 4.2 Global GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)

Figure 5.1 Global GVHD Market by product 2016-2027 ($m)

Figure 5.2 Global GVHD Market by Product: Market Share (%), 2016

Figure 5.3 Global GVHD Market by Product: Market Share (%), 2022

Figure 5.4 Global GVHD Market by Product: Market Share (%), 2027

Figure 6.1 Global GVHD Market: Revenue ($m) by Region, 2016

Figure 6.2 Global GVHD: Market Share (%) by Region, 2016

Figure 6.3 United States GVHD market Forecast: 2016-2027 ($m, AGR %)

Figure 6.4 United States GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)

Figure 6.5 United States GVHD Market by Treatment Type: Market Share (%), 2016

Figure 6.6 United States GVHD Market by Treatment Type: Market Share (%), 2022

Figure 6.7 United States GVHD Market by Treatment Type: Market Share (%), 2027

Figure 6.8 U.S. GVHD Patient Number Forecast, 2013-2026

Figure 6.9 U.S. GVHD Patient Number Forecast, 2019-2029

Figure 6.10 Japan GVHD market Forecast:2016-2027 ($m, AGR %)

Figure 6.11 Japan GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)

Figure 6.12 Japan GVHD Market by Treatment Type: Market Share (%), 2016

Figure 6.13 Japan GVHD Market by Treatment Type: Market Share (%), 2022

Figure 6.14 Japan GVHD Market by Treatment Type: Market Share (%), 2027

Figure 6.15 Japan GVHD Patient Number Forecast, 2013-2026

Figure 6.16 Japan GVHD Patient Number Forecast, 2019-2029

Figure 6.17 France GVHD market Forecast: 2016-2027 ($m, AGR %)

Figure 6.18 France GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)

Figure 6.19 France GVHD Market by Treatment Type: Market Share (%), 2016

Figure 6.20 France GVHD Market by Treatment Type: Market Share (%), 2022

Figure 6.21 France GVHD Market by Treatment Type: Market Share (%), 2027

Figure 6.22 France GVHD Patient Number Forecast, 2013-2026

Figure 6.23 France GVHD Patient Number Forecast, 2019-2029

Figure 6.24 Germany GVHD market Forecast: 2016-2027 ($m, AGR %)

Figure 6.25 Germany GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)

Figure 6.26 Germany GVHD Market by Treatment Type: Market Share (%), 2016

Figure 6.27 Germany GVHD Market by Treatment Type: Market Share (%), 2022

Figure 6.28 Germany GVHD Market by Treatment Type: Market Share (%), 2027

Figure 6.29 Germany GVHD Patient Number Forecast, 2013-2026

Figure 6.30 Germany GVHD Patient Number Forecast, 2019-2029

Figure 6.31 Italy GVHD market Forecast: 2016-2027 ($m, AGR %)

Figure 6.32 Italy GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)

Figure 6.33 Italy GVHD Market by Treatment Type: Market Share (%), 2016

Figure 6.34 Italy GVHD Market by Treatment Type: Market Share (%), 2022

Figure 6.35 Italy GVHD Market by Treatment Type: Market Share (%), 2027

Figure 6.36 Italy GVHD Patient Number Forecast, 2013-2026

Figure 6.37 Italy GVHD Patient Number Forecast, 2019-2029

Figure 6.38 Spain GVHD market Forecast: 2016-2027 ($m, AGR %)

Figure 6.39 Spain GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)

Figure 6.40 Spain GVHD Market by Treatment Type: Market Share (%), 2016

Figure 6.41 Spain GVHD Market by Treatment Type: Market Share (%), 2022

Figure 6.42 Spain GVHD Market by Treatment Type: Market Share (%), 2027

Figure 6.43 Spain GVHD Patient Number Forecast, 2013-2026

Figure 6.44 Spain GVHD Patient Number Forecast, 2019-2029

Figure 6.45 United Kingdom GVHD market Forecast: 2016-2027 ($m, AGR %)

Figure 6.46 United Kingdom GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)

Figure 6.47 United Kingdom GVHD Market by Treatment Type: Market Share (%), 2016

Figure 6.48 United Kingdom GVHD Market by Treatment Type: Market Share (%), 2022

Figure 6.49 United Kingdom GVHD Market by Treatment Type: Market Share (%), 2027

Figure 6.50 United Kingdom GVHD Patient Number Forecast, 2013-2026

Figure 6.51 United Kingdom GVHD Patient Number Forecast, 2019-2029

Figure 7.1 Temcell: Sales ($m), 2016-2027

Figure 7.2 Remicade: Sales ($m), 2016-2027

Figure 7.3 Lemtrada: Sales ($m), 2016-2027

Figure 7.4 Velcade: Sales ($m), 2016-2027

Figure 7.5 Gleevac: Sales ($m), 2016-2027

Figure 7.6 Rapamune: Sales ($m), 2016-2027

Figure 7.7 Enbrel: Sales ($m), 2016-2027

Figure 7.8 Orencia: Sales ($m), 2016-2027

Figure 7.9 Nulojix: Sales ($m), 2016-2027

Figure 7.10 ATG-Fresenius: Sales ($m), 2016-2027

Figure 8.1 Leukotac: Sales ($m), 2016-2027

Figure 8.2 Begelomab: Sales ($m), 2016-2027

Figure 8.3 Budesonide/Budenofalk: Sales ($m), 2016-2027

Figure 11.1 Global Graft versus Host Disease (GVHD) Market: Revenue ($m), 2016, 2022, 2027

Figure 11.2 Global Graft versus Host Disease (GVHD) Market: Revenue ($m), by Region, 2016, 2022, 2027

Figure 11.3 Global Graft versus Host Disease (GVHD) Market: Revenue ($m) by Segment, 2016, 2022, 2027

Adienne Pharma & Biotech

Amgen, Inc.

Bristol Myers Squibb (BMS)

Committee for Medicinal Products for Human Use (CHMP)

Dr. Falk Pharma GmbH

European Commission

Fate Therapeutics

Fresenius Biotech

Genzyme

Jazz Pharmaceuticals

JCR Pharmaceuticals

Johnson & Johnson

Kymab Group Limited

MolMed

Neovii Biotech

Novartis

OncoImmune

Pfizer

Pharmaceuticals and Medical Devices Agency (PMDA)

Sanofi

Takeda Pharmaceutical Company Limited

Targazyme, Inc.

US FDA

Download sample pages

Complete the form below to download your free sample pages for Global Graft versus Host Disease (GVHD) Market 2019-2029

Download sample pages

Complete the form below to download your free sample pages for Global Graft versus Host Disease (GVHD) Market 2019-2029

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

31 May 2023

READ

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

26 May 2023

READ

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

24 May 2023

READ

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

23 May 2023

READ

Industries > Pharma > Global Graft versus Host Disease (GVHD) Market 2019-2029

Back to Pharma Reports

Global Graft versus Host Disease (GVHD) Market 2019-2029

Acute, Chronic and Prophylaxis GVHD

Download sample pages

Related reports

Global Translational Regenerative Medicine Market Prospects 2018-2028

Biobanking Market Forecasts 2019-2029

Global Stem Cell Technologies and Applications Market 2020-2030

Global Stem Cell Technologies and Applications Market 2018-2028

Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029

Biobanking Market Forecasts 2018-2028

Global Transplant Market Forecast 2019-2029

Gene Therapy R&D and Revenue Forecasts 2018-2028

Global Precision Medicine Market Forecast 2019-2029

Top 25 Translational Regenerative Medicine Manufacturers 2019

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

Our Clients